Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? (Q26777994)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author

Juan F Navarro-González

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Jose Luis Górriz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Javier Nieto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Pablo Molina

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Alberto Martínez-Castelao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Luis M Pallardó

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

23 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Medicine

28 February 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1866-1889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

28 February 2020

copyright license

start time

23 October 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Renal effects of dapagliflozin in patients with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Glucose control and vascular complications in veterans with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Dapagliflozin in patients with type 2 diabetes mellitus.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Diabetic nephropathy - complications and treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The potential for renoprotection with incretin-based drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Epidemiology of diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Metformin's contraindications should be contraindicated.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Tubuloglomerular feedback and the control of glomerular filtration rate

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Distribution of GLP-1 and PACAP receptors in human tissues

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Effect of a multifactorial intervention on mortality in type 2 diabetes

31 May 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Rosiglitazone decreases albuminuria in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Sitagliptin reduces albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM4101866

Metformin and renal injury protection

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4626660

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells

28 November 2018

1 reference

12 December 2020

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Adenosine deaminase-complexing protein from bovine kidney. Isolation of two distinct subunits

1 reference

12 December 2020

Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat

1 reference

12 December 2020

Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats

1 reference

12 December 2020

Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats

1 reference

12 December 2020

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

1 reference

12 December 2020

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes

1 reference

12 December 2020

Insulin sensitivity and albuminuria: the RISC study

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

1 reference

12 December 2020

Identifiers

DOI

10.3390/JCM4101866

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

26512703

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26512703%20AND%20SRC:MED&resulttype=core&format=json